Aqueous leaf extract from Luehea divaricata Mart. Modulates oxidative stress markers in the spinal cord of rats with neuropathic pain

Kroth, Adarly; Santos, Maria do Carmo Quevedo; Silva, Thaisla Cristiane Borella da; Silveira, Elza Maria Santos da; Partata, Wania Aparecida

doi:10.1016/j.jep.2020.113674

Cited by 7 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, systemic or intrathecal post-treatment with ROS scavengers significantly reduced hyperalgesia in a mouse model of capsaicin-induced pain (20). Glutathione also exerts an analgesic effect in models of neuropathic pain by reducing the ROS content and increasing the expression of antioxidant enzymes (21). In a a previous study, in rats with cancer-induced bone pain, the inhibition of the oxidative stress response and the elevation of the activity of the antioxidant enzyme, superoxide dismutase (SOD), reduced the pain sensitivity of rats (22).…”

Section: Introductionmentioning

confidence: 99%

LY294002 alleviates bone cancer pain by reducing mitochondrial dysfunction and the inflammatory response

et al. 2023

View full text Add to dashboard Cite

Bone cancer pain (BCP) is mainly caused by bone metastasis and markedly impairs the functional capacity and daily functions of patients. Neuroinflammation plays a pivotal role in the pathogenesis and maintenance of chronic pain. Oxidative stress in the mitochondria is a key contributor to neuroinflammation and neuropathic pain. Herein, a rat model of BCP was established which was characterized by bone destruction, pain hypersensitivity and motor disability. In the spinal cord, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling was activated, and the inflammatory response and mitochondrial dysfunction were also observed. The intrathecal injection of LY294002, a selective inhibitor of PI3K/Akt signaling, decreased mechanical pain sensitivity, suppressed spontaneous pain and recovered the motor coordination of rats with BCP. Second, LY294002 treatment blocked spinal inflammation by reducing astrocytic activation and downregulating the expression levels of inflammatory factors, such as NF-κB, IL-1β and TNF-α. Moreover, LY294002 treatment recovered mitochondrial function by activating the manganese superoxide dismutase enzyme, increasing NADH:ubiquinone oxidoreductase subunit B11 expression, and decreasing BAX and dihydroorotate dehydrogenase expression. LY294002 treatment also increased the mitochondrial membrane potential and decreased the mitochondrial reactive oxygen species levels in C6 cells. On the whole, the results of the present study suggest that the inhibition of PI3K/Akt signaling by LY294002 restores mitochondrial function, suppresses spinal inflammation and alleviates BCP.

show abstract

Section: Introductionmentioning

confidence: 99%

LY294002 alleviates bone cancer pain by reducing mitochondrial dysfunction and the inflammatory response

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Neuropathic pain (NP) is normally caused by lesions in the nervous system and leads to long-term debilitating conditions, which reduce the quality of life. Pathophysiological changes in patients with NP result in anxiety, depression, and elevated blood pressure ( Kroth et al , 2020 ). There are several types of NP, including painful non-diabetic neuropathy, trigeminal neuralgia, multiple sclerosis, and spinal cord injury ( Bouhassira, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Overexpression of RAPGEF3 enhances the therapeutic effect of dezocine in treatment of neuropathic pain

Xue

Song

et al. 2021

Genet. Mol. Biol.

View full text Add to dashboard Cite

Pain is a significant problem worldwide that affects the quality of life of patients. Dezocine is a non-addictive analgesic drug with kappa-opioid antagonist activity and has been successfully used to alleviate of postoperative pain. In addition, dezocine has an analgesic effect similar to that of morphine, alleviating moderate to severe pain. Rap guanine nucleotide exchange factor 3 (RAPGEF3) is a guanine nucleotide exchange factor for GTPases Rap1 and Rap2, which could enhance the activity of Rap1 to promote cell adhesion and axon regeneration, as well as promote neurite extension by interacting with nerve growth factors. Here, we first observed that overexpression of RAPGEF3 increased cell viability, as shown by a CCK-8 assay, and recovered brain function in rats. The expression of inflammation-related factors at the mRNA level was detected using qPCR, and the concentration of these factors in a cultured cell medium and rat serum samples were decreased as shown by ELISA after RAPGEF3 overexpression. Through western blotting, we further found that pro-inflammatory proteins were decreased, and these effects might be mediated by inhibition of the Ras/p-38 MAPK signaling pathway. Taken together, we speculated that RAPGEF3overexpression enhances the therapeutic effect of dezocine on neuropathic pain by inhibiting the inflammatory response through inhibition of the Ras/p-38 MAPK signaling pathway.

show abstract

Analgesic potency of intrathecally administered punicalagin in rat neuropathic and inflammatory pain models

2021

View full text Add to dashboard Cite

Aqueous leaf extract from Luehea divaricata Mart. Modulates oxidative stress markers in the spinal cord of rats with neuropathic pain

Cited by 7 publications

References 46 publications

LY294002 alleviates bone cancer pain by reducing mitochondrial dysfunction and the inflammatory response

LY294002 alleviates bone cancer pain by reducing mitochondrial dysfunction and the inflammatory response

Overexpression of RAPGEF3 enhances the therapeutic effect of dezocine in treatment of neuropathic pain

Analgesic potency of intrathecally administered punicalagin in rat neuropathic and inflammatory pain models

Contact Info

Product

Resources

About